Lupin shares gain ahead of US drug launch that can fetch $200 million in FY26

With this launch, Lupin’s FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to Lupin’s FY26 earnings.

Leave a Reply

Your email address will not be published. Required fields are marked *